Statsols Blog

Clinical trial combo started by Amgen and Merck

Combo clinical trial from Amgen and Merck

Amgen and Merck have launched an early-stage clinical trial pairing their respective cancer immunotherapies, looking to confirm the clinical and commercial promise of combination approaches to cancer.

The two companies have dosed their first subject in a planned 110-patient clinical trial, administering Amgen's cancer vaccine T-Vec alongside Merck's PD-1-blocking pembrolizumab, approved as Keytruda, to see how well the cocktail can treat melanoma.

About the Combination Clinical Trial:

The multicenter, open-label clinical trial is designed to evaluate the safety of talimogene laherparepvec in combination with KEYTRUDA, as well as the efficacy of this combination versus KEYTRUDA alone and following progression after treatment with KEYTRUDA alone.

The clinical trial study will be conducted in two phases:

  • Phase 1 will determine the safety and tolerability of talimogene laherparepvec in combination with KEYTRUDA in patients with previously untreated, unresected, stage IIIB to IVM1c melanoma.
  • The randomized phase will further evaluate the safety and efficacy of talimogene laherparepvec in combination with KEYTRUDA.


For more information please click here

Topics: Uncategorized